MX338024B - Derivado de dibencilamina opticamente activa y metodo para prepararla. - Google Patents

Derivado de dibencilamina opticamente activa y metodo para prepararla.

Info

Publication number
MX338024B
MX338024B MX2012014149A MX2012014149A MX338024B MX 338024 B MX338024 B MX 338024B MX 2012014149 A MX2012014149 A MX 2012014149A MX 2012014149 A MX2012014149 A MX 2012014149A MX 338024 B MX338024 B MX 338024B
Authority
MX
Mexico
Prior art keywords
manufacturing
same
optically active
derivative
dibenzylamine derivative
Prior art date
Application number
MX2012014149A
Other languages
English (en)
Other versions
MX2012014149A (es
Inventor
Tadaaki Ohgiya
Koichi Yamazaki
Katsutoshi Miyosawa
Takeshi Murakami
Kimiyuki Shibuya
Taichi Kusakabe
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2012014149A publication Critical patent/MX2012014149A/es
Publication of MX338024B publication Critical patent/MX338024B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

El ácido (S)-trans-{4-[({2-[({1-[3,5-bis (trifluorometil) fenil] etil}{5-[2-(metilsulfonil)etoxi]pirimidin-2-il}amino)metil]-4-(tr ifluorometil)fenil} (etil)amino)metil]ciclohexil}acético sustancialmente ópticamente puro, o una sal de él o un solvato de él, que tiene acciones de reducción de la cantidad de proteína PCSK9 y aumento de la cantidad del receptor de LDL.
MX2012014149A 2010-06-04 2011-06-03 Derivado de dibencilamina opticamente activa y metodo para prepararla. MX338024B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010128585 2010-06-04
JP2010218299 2010-09-29
PCT/JP2011/062751 WO2011152508A1 (ja) 2010-06-04 2011-06-03 光学活性ジベンジルアミン誘導体及びその製造方法

Publications (2)

Publication Number Publication Date
MX2012014149A MX2012014149A (es) 2013-02-27
MX338024B true MX338024B (es) 2016-03-31

Family

ID=45066863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014149A MX338024B (es) 2010-06-04 2011-06-03 Derivado de dibencilamina opticamente activa y metodo para prepararla.

Country Status (17)

Country Link
US (1) US8906895B2 (es)
EP (1) EP2578574B1 (es)
JP (1) JP5555320B2 (es)
KR (2) KR20130111512A (es)
CN (2) CN102933559B (es)
AU (1) AU2011259929B2 (es)
BR (1) BR112012030787A2 (es)
CA (1) CA2801417C (es)
EA (1) EA024241B1 (es)
ES (1) ES2581557T3 (es)
IL (1) IL223377A (es)
IN (1) IN2012CN10925A (es)
MX (1) MX338024B (es)
PT (1) PT2578574E (es)
TW (1) TWI492749B (es)
WO (1) WO2011152508A1 (es)
ZA (1) ZA201209372B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2013CN01326A (es) 2010-07-22 2015-04-24 Kowa Co
US20130225618A1 (en) * 2010-10-04 2013-08-29 Kowa Co., Ltd. Agent for inhibiting expression of lipid metabolism related mrna
JPWO2013080999A1 (ja) * 2011-11-29 2015-04-27 興和株式会社 ＮＰＣ１Ｌ１及び／又はＬＩＰＧｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤
TW201335109A (zh) * 2011-12-02 2013-09-01 Kowa Co 光學活性化合物之製造方法
WO2013137371A1 (ja) * 2012-03-15 2013-09-19 興和株式会社 新規ピリミジン化合物及びそれらを含有する医薬
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
US9682942B2 (en) * 2013-05-31 2017-06-20 Kowa Company, Ltd. Form of pyrimidine compound having dibenzylamine structure
JP2017528448A (ja) * 2014-08-21 2017-09-28 エスアールエックス カーディオ，エル エル シー プロタンパク質コンバターゼであるスブチリシン／ケキシンタイプ９（ｐｃｓｋ９）のタンパク質活性のモジュレーションのための、結合リガンドとしての小分子の組成物およびその使用方法
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
WO2016084950A1 (ja) * 2014-11-28 2016-06-02 興和株式会社 医薬組成物
US20170252338A1 (en) * 2014-11-28 2017-09-07 Kowa Company, Ltd. Medicine
JP2019131472A (ja) * 2016-05-31 2019-08-08 興和株式会社 医薬組成物
RS66416B1 (sr) * 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
EP3911640A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189208A (en) * 1991-07-01 1993-02-23 Ethyl Corporation Ibuprofen resolution
NZ580777A (en) * 2007-04-13 2011-05-27 Kowa Co Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
US8673850B2 (en) * 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
US20130225618A1 (en) 2010-10-04 2013-08-29 Kowa Co., Ltd. Agent for inhibiting expression of lipid metabolism related mrna

Also Published As

Publication number Publication date
IL223377A0 (en) 2013-03-05
TW201208688A (en) 2012-03-01
US8906895B2 (en) 2014-12-09
PT2578574E (pt) 2016-06-17
JP5555320B2 (ja) 2014-07-23
EP2578574A1 (en) 2013-04-10
KR20170078865A (ko) 2017-07-07
MX2012014149A (es) 2013-02-27
EP2578574A4 (en) 2013-12-04
HK1179959A1 (en) 2013-10-11
BR112012030787A2 (pt) 2020-09-01
US20130225814A1 (en) 2013-08-29
CN102933559B (zh) 2016-01-27
JPWO2011152508A1 (ja) 2013-08-01
AU2011259929A1 (en) 2013-01-17
ZA201209372B (en) 2014-02-26
IN2012CN10925A (es) 2015-04-24
EA024241B1 (ru) 2016-08-31
CN102933559A (zh) 2013-02-13
CN104529910A (zh) 2015-04-22
CN104529910B (zh) 2017-05-10
IL223377A (en) 2016-12-29
EA201291447A1 (ru) 2013-05-30
CA2801417C (en) 2017-07-11
KR20130111512A (ko) 2013-10-10
ES2581557T3 (es) 2016-09-06
AU2011259929B2 (en) 2014-07-31
EP2578574B1 (en) 2016-04-27
WO2011152508A1 (ja) 2011-12-08
CA2801417A1 (en) 2011-12-08
TWI492749B (zh) 2015-07-21

Similar Documents

Publication Publication Date Title
MX338024B (es) Derivado de dibencilamina opticamente activa y metodo para prepararla.
EA201390815A1 (ru) Лечение jak2-опосредованных состояний
CL2008002142A1 (es) Compuestos derivados de 2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}tio)-4-[4-(2-hidroxietoxi) fenil] piridin-3,5-dicarbonitrilo; procedimiento de preparacion; composicion farmaceutica y uso en enfermedades cardiovasculares.
DK2097381T3 (da) 4-[4-({[4-chlor-3-(trifluormethyl)phenyl)]carbamoyl}amino)-3-fluorphenoxy]-N-methylpyridin-2-carboxamidmonohydrat
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
LT3034497T (lt) 3,5-diamino-6-chlor-n-(n-(4-(4-(2-(heksil(2,3,4,5,6-penta-hidroksiheksil)amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamidas
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
EA200702541A1 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
PE20100083A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
NZ602125A (en) Uses of dgat1 inhibitors
EP2279244A4 (en) METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
DK3252069T3 (da) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-oner til behandling af sygdomme
CO6361988A2 (es) Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
CL2007001692A1 (es) Sal de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de proteina.
MX2010003989A (es) Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
CL2024000758A1 (es) Sal de trometamina de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético
MX379709B (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
CL2011003138A1 (es) N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion.
DK2300452T3 (da) 5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister
BR112013010704A2 (pt) uma composição compreendendo s-[2-([[1-(2-etilbutila)-ciclohexila]-carbonila]amino)fenila]2-metilpropanotioato e croscarmelose de sódio
IL179346A0 (en) 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
CY1110942T1 (el) Αλας αιθανολαμινης n-(3-μεθοξυ-αιθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολο -2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδιου
CL2008002857A1 (es) Sal de (-) 4-(4-fluorofenil)-7-[({5-[1-hidroxi-1-(trifluorometil)propil]-1,3,4-oxadiazol-2-il}amino)metil]-2h-cromen-2-ona, composicion farmaceutica, util para el tratamiento de una enfermedad seleccionada de asma, enfermedad pulmonar obstructiva cronica y arterosclerosis.

Legal Events

Date Code Title Description
FG Grant or registration